Bladder Cancer Summary
Epidemiology:
- Most common type: Urothelial carcinoma (90-95% of cases).
- Risk factors:
- Smoking (most significant risk factor).
- Occupational exposure to chemicals (e.g., aromatic amines, dyes, rubber, paint).
- Chronic bladder irritation (e.g., recurrent UTIs, indwelling catheters, schistosomiasis).
- Age >55, male gender, Caucasian race.
- Genetic predisposition (e.g., Lynch syndrome).
---
Clinical Presentation:
- Most common symptom: Painless gross hematuria (85% of cases).
- Other symptoms:
- Microscopic hematuria.
- Irritative voiding symptoms (e.g., dysuria, urgency, frequency).
- Flank pain (if ureteral obstruction occurs).
- Advanced disease: Weight loss, pelvic pain, or bone pain (metastasis).
---
Diagnosis:
1. Urinalysis:
- Hematuria (gross or microscopic).
- May show malignant cells on urine cytology (more sensitive for high-grade tumors).
2. Cystoscopy:
- Gold standard for diagnosis.
- Allows direct visualisation and biopsy of suspicious lesions.
3. Imaging:
- CT urogram: Evaluates upper urinary tract (kidneys, ureters) for synchronous tumors.
- **MRI or CT abdomen/pelvis:** Staging for muscle-invasive disease.
4. Transurethral resection of bladder tumor (TURBT):
- Diagnostic and therapeutic for non-muscle-invasive tumors.
- Provides histologic grade and stage.
---
Staging (TNM System):
- Non-muscle-invasive bladder cancer (NMIBC):
- Ta: Non-invasive papillary carcinoma.
- Tis: Carcinoma in situ (flat, high-grade).
- T1: Invades lamina propria.
- Muscle-invasive bladder cancer (MIBC):
- T2: Invades muscularis propria.
- T3: Invades perivesical tissue.
- T4: Invades adjacent organs (e.g., prostate, uterus, pelvic wall).
- **Metastatic disease:** N1-N3 (lymph nodes), M1 (distant metastasis).
---
Management:
1. **Non-Muscle-Invasive Bladder Cancer (NMIBC):**
- **TURBT:** Initial treatment for Ta/T1 tumors.
- **Intravesical therapy:**
- **BCG (Bacillus Calmette-Guérin):** For high-grade tumors or carcinoma in situ (CIS).
- **Mitomycin C:** For intermediate-risk tumors.
- **Surveillance:** Regular cystoscopy and urine cytology.
2. **Muscle-Invasive Bladder Cancer (MIBC):**
- **Radical cystectomy:** Gold standard for localized disease.
- **Neoadjuvant chemotherapy:** Cisplatin-based regimens before surgery.
- **Bladder preservation:** Radiation + chemotherapy for select patients.
3. Metastatic Disease:
- **Systemic chemotherapy:** Cisplatin-based regimens (e.g., MVAC, gemcitabine + cisplatin).
- **Immunotherapy:** Checkpoint inhibitors (e.g., pembrolizumab, atezolizumab).
---
Prognosis:
- NMIBC:** Good prognosis with 5-year survival >90% for low-grade tumors.
- MIBC:** 5-year survival ~50-60% with treatment.
- Metastatic disease:** Poor prognosis, median survival ~12-15 months.
---
Key Points for MCCQE1 and Step 2:
- Painless hematuria in an older adult with smoking history = suspect bladder cancer.
- Cystoscopy + TURBT is diagnostic and therapeutic for NMIBC.
- BCG is first-line for high-grade NMIBC or CIS.
- Radical cystectomy is the gold standard for MIBC.
- Neoadjuvant cisplatin-based chemotherapy improves survival in MIBC.
- Most common type: Urothelial carcinoma (90-95% of cases).
- Risk factors:
- Smoking (most significant risk factor).
- Occupational exposure to chemicals (e.g., aromatic amines, dyes, rubber, paint).
- Chronic bladder irritation (e.g., recurrent UTIs, indwelling catheters, schistosomiasis).
- Age >55, male gender, Caucasian race.
- Genetic predisposition (e.g., Lynch syndrome).
---
Clinical Presentation:
- Most common symptom: Painless gross hematuria (85% of cases).
- Other symptoms:
- Microscopic hematuria.
- Irritative voiding symptoms (e.g., dysuria, urgency, frequency).
- Flank pain (if ureteral obstruction occurs).
- Advanced disease: Weight loss, pelvic pain, or bone pain (metastasis).
---
Diagnosis:
1. Urinalysis:
- Hematuria (gross or microscopic).
- May show malignant cells on urine cytology (more sensitive for high-grade tumors).
2. Cystoscopy:
- Gold standard for diagnosis.
- Allows direct visualisation and biopsy of suspicious lesions.
3. Imaging:
- CT urogram: Evaluates upper urinary tract (kidneys, ureters) for synchronous tumors.
- **MRI or CT abdomen/pelvis:** Staging for muscle-invasive disease.
4. Transurethral resection of bladder tumor (TURBT):
- Diagnostic and therapeutic for non-muscle-invasive tumors.
- Provides histologic grade and stage.
---
Staging (TNM System):
- Non-muscle-invasive bladder cancer (NMIBC):
- Ta: Non-invasive papillary carcinoma.
- Tis: Carcinoma in situ (flat, high-grade).
- T1: Invades lamina propria.
- Muscle-invasive bladder cancer (MIBC):
- T2: Invades muscularis propria.
- T3: Invades perivesical tissue.
- T4: Invades adjacent organs (e.g., prostate, uterus, pelvic wall).
- **Metastatic disease:** N1-N3 (lymph nodes), M1 (distant metastasis).
---
Management:
1. **Non-Muscle-Invasive Bladder Cancer (NMIBC):**
- **TURBT:** Initial treatment for Ta/T1 tumors.
- **Intravesical therapy:**
- **BCG (Bacillus Calmette-Guérin):** For high-grade tumors or carcinoma in situ (CIS).
- **Mitomycin C:** For intermediate-risk tumors.
- **Surveillance:** Regular cystoscopy and urine cytology.
2. **Muscle-Invasive Bladder Cancer (MIBC):**
- **Radical cystectomy:** Gold standard for localized disease.
- **Neoadjuvant chemotherapy:** Cisplatin-based regimens before surgery.
- **Bladder preservation:** Radiation + chemotherapy for select patients.
3. Metastatic Disease:
- **Systemic chemotherapy:** Cisplatin-based regimens (e.g., MVAC, gemcitabine + cisplatin).
- **Immunotherapy:** Checkpoint inhibitors (e.g., pembrolizumab, atezolizumab).
---
Prognosis:
- NMIBC:** Good prognosis with 5-year survival >90% for low-grade tumors.
- MIBC:** 5-year survival ~50-60% with treatment.
- Metastatic disease:** Poor prognosis, median survival ~12-15 months.
---
Key Points for MCCQE1 and Step 2:
- Painless hematuria in an older adult with smoking history = suspect bladder cancer.
- Cystoscopy + TURBT is diagnostic and therapeutic for NMIBC.
- BCG is first-line for high-grade NMIBC or CIS.
- Radical cystectomy is the gold standard for MIBC.
- Neoadjuvant cisplatin-based chemotherapy improves survival in MIBC.
Comments
Post a Comment